Congenital hyperthyroidism is less frequent than congenital hypothyroidism but its impact on growth and development can be as dramatic. The immune form of hyperthyroidism that is transmitted from a mother with Graves’ disease to her foetus and then neonate is transient, but cases of persistent congenital hyperthyroidism had also been described, that can now be explained by molecular abnormalities of the thyrotropin receptor. The abundance of published data on the neonatal effects of maternal Graves’ disease contrasts with the paucity of information on fetal effects. Recent studies showed that it is of utmost to scrutinize fetal thyroid by expert ultrasonographist and to have a team work with obstetricians and pediatric endocrinologists in pregnant women with Graves’ disease. This allowed to accurately determine the fetal thyroid status and to adapt the treatment in the mothers successfully. Fetal hyperthyroidism does exist and needs an appropriate aggressive treatment. Clearly the fetus has become our patient!

Keywords:
Congenital hyperthyroidism, Fetal medicine, Goiter, TSH receptor, Fetus, Ultrasonography, Thyroid hormone, Graves’disease, Thyroid stimulating immunoglobulins
1.
Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S: Fetal loss associated with excess thyroid hormone exposure. JAMA 2004;292:691–695.
2.
Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, et al: Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995;332:150–154.
3.
Polak M, Le Gac I, Vuillard E, Guibourdenche J, Leger J, Toubert ME, et al: Fetal and neonatal thyroid function in relation to maternal Graves’ disease. Best Pract Res Clin Endocrinol Metab 2004;18:289–302.
4.
Luton D, Le Gac I, Vuillard E, Castanet M, Guibourdenche J, Noel M, et al: Management of Graves’disease during pregnancy: the key role of foetal thyroid gland monitoring. J Clin Endocrinol Metab 2005;90:6093–6098.
5.
De Felice M, Di Lauro R: Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev 2004;25:722–746.
6.
Polak M, Sura-Trueba S, Chauty A, Szinnai G, Carre A, Castanet M: Molecular mechanisms of thyroid dysgenesis. Horm Res 2004;62(suppl 3):14–21.
7.
Olin P, Vecchio G, Ekholm R, Almquist S: Biosynthesis of thyroglobulin related to the ultrastructure of the human fetal thyroid gland. Endocrinology 1970;86:1041–1048.
8.
Shepard TH: Onset of function in the human fetal thyroid: biochemical and radioautographic studies from organ culture. J Clin Endocrinol Metab 1967;27:945–958.
9.
Szinnai G, Lacroix, Guimiot F, Talbot M, Martinovic J, Delezoide AL, Vekemans M, Michiels S, Caillou B, Schlumberger M, Bidart JM, Polak M: Ontogeny of thyroid function in the human fetus: the sodium/iodide symporter (NIS) is the gatekeeper of thyroid hormone synthesis. LWPES/ESPE Lyon 21–24 sept 2005; Horm Res 2005;64(suppl):355–1224.
10.
Vulsma T, Gons MH, de Vijlder JJ: Maternal-fetal transfer of thyroxine in congenital hypothyroidism due to a total organification defect or thyroid agenesis. N Engl J Med 1989;321:13–16.
11.
Morreale de Escobar G, Obregón MJ, Escobar del Rey F: Is neuropsychological development related to maternal hypothyroidism or to maternal hypothyroxinemia? J. Clin. Endocrinol. Metab 2000;85:3975–3987.
12.
Polak M: Hyperthyroidism in early infancy: pathogenesis, clinical features and diagnosis with a focus on neonatal hyperthyroidism. Thyroid 1998;8:1171–1177.
13.
Davies TF, Ando T, Lin RY, Tomer Y, Latif R: Thyrotropin receptor-associated diseases: from adenoma to Grave disease. J Clin Invest 2005;115:1972–1983.
14.
Zakarija M, McKenzie JM: Pregnancy-associated changes in the thyroid-stimulating antibody of Graves’ disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 1983;57:1036–1040.
15.
Brown RS, Bellisario RL, Botero D, Fournier L, Abrams CA, Cowger ML, et al. Incidence of transient congenital hypothyroidism due to maternal thyrotropin receptor-blocking antibodies in over one million babies. J Clin Endocrinol Metab 1996;81:1147–1151.
16.
Hollingsworth DR, Mabry CC, Eckerd JM: Hereditary aspects of Graves’ disease in infancy and childhood. J Pediatr 1972;81:446–459.
17.
Thomas JS, Leclere J, Hartemann P, Duheille J, Orgiazzi J, Petersen M, et al. Familial hyperthyroidism without evidence of autoimmunity. Acta Endocrinol (Copenh) 1982;100:512–518.
18.
Duprez L, Parma J, Van Sande J, Allgeier A, Leclere J, Schvartz C, et al: Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994;7:396–401.
19.
de Roux N, Polak M, Couet J, Leger J, Czernichow P, Milgrom E, et al: A neomutation of the thyroid-stimulating hormone receptor in a severe neonatal hyperthyroidism. J Clin Endocrinol Metab 1996;81:2023–2026.
20.
Yoshimoto M, Nakayama M, Baba T, Uehara Y, Niikawa N, Ito M, et al: A case of neonatal McCune-Albright syndrome with Cushing syndrome and hyperthyroidism. Acta Paediatr Scand 1991;80:984–987.
21.
Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Boney CM, et al: Severe endocrine and nonendocrine manifestations of the McCune-Albright syndrome associated with activating mutations of stimulatory G protein GS. J Pediatr 1993;123:509–518.
22.
Leclere J, Bene MC, Aubert V, Klein M, Pascal-Vigneron V, Weryha G, et al: Clinical consequences of activating germline mutations of TSH receptor, the concept of toxic hyperplasia. Horm Res 1997;47:158–162.
23.
Duprez L, Parma J, Van Sande J, Rodien P, Sabine C, Abramowicz M, et al: Pathology of the TSH receptor. J Pediatr Endocrinol Metab 1999;12(suppl 1):295–302.
24.
Kopp P, Muirhead S, Jourdain N, Gu WX, Jameson JL, Rodd C: Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a novel somatic mutation (serine281–>isoleucine) in the extracellular domain of the thyrotropin receptor. J Clin Invest 1997;100:1634–1639.
25.
Skuza KA, Sills IN, Stene M, Rapaport R: Prediction of neonatal hyperthyroidism in infants born to mothers with Graves disease. J Pediatr 1996;128:264–268.
26.
Ranzini AC, Ananth CV, Smulian JC, Kung M, Limbachia A, Vintzileos AM: Ultrasonography of the fetal thyroid: nomograms based on biparietal diameter and gestational age. J Ultrasound Med 2001;20:613–617.
27.
Nachum Z, Rakover Y, Weiner E, Shalev E: Graves’ disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. Am J Obstet Gynecol 2003;189:159–165.
28.
Luton D, Fried D, Sibony O, Vuillard E, Tebeka B, Boissinot C, Leger J, Polak M, Oury JF, Blot P: Assessment of fetal thyroid function by colored Doppler echography. Fetal Diagn Ther 1997;12:24–27.
29.
Daffos F, Capella-Pavlovsky M, Forestier F: Fetal blood sampling during pregnancy with use of a needle guided by ultrasound: a study of 606 consecutive cases. Am J Obstet Gynecol 1985;153:655–656.
30.
Transue D, Chan J, Kaplan M: Management of neonatal Graves disease with iopanoic acid. J Pediatr 1992;121:472–474.
31.
Kempers MJE, Van Tijn DA, Van Trotsenburg PAS, De Vijlder JJM, Wiedijk BM, Vulsma T: Central congenital hypothyroidism due to gestational hyperthyroidism: detection where prevention failed. J Clin Endocrinol Metab 2003;88:5851–5857.
32.
Foulds N, Walpole I, Elmslie F, Mansour S: Carbimazole embryopathy: an emerging phenotype. Am J Med Genet 2005;132:130–135.
33.
Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J: Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol 1998;139:584–586.
34.
Luton D, Le Gac I, Noel M, Guibourdenche J, Polak M: Thyroid Function during Pregnancy in Women with Past Graves’ disease. Br J Obstet Gynaecol 2005;112:1565–1567.
35.
Daneman D, Howard NJ: Neonatal thyrotoxicosis: intellectual impairment and craniosynostosis in later years. J Pediatr 1980;97:257–259.
36.
Messer PM, Hauffa BP, Olbricht T, Benker G, Kotulla P, Reinwein D: Antithyroid drug treatment of Graves’ disease in pregnancy: long-term effects on somatic growth, intellectual development and thyroid function of the offspring. Acta Endocrinol (Copenh) 1990;123:311–316.
37.
Smith C, Thomsett M, Choong C, Rodda C, McIntyre HD, Cotterill AM: Congenital thyrotoxicosis in premature infants. Clin Endocrinol (Oxf) 2001;54:371–376.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.